Precision BioSciences, Inc. Has Entered Into An Amended And Restated Development And License Agreement With Prevail Therapeutics Inc., A Subsidiary Of Eli Lilly And Company, To Collaborate On Developing Potential In Vivo Therapies For Genetic Disorders
Portfolio Pulse from Happy Mohamed
Precision BioSciences, Inc. has amended and restated its development and license agreement with Prevail Therapeutics Inc., a subsidiary of Eli Lilly and Company, to collaborate on developing potential in vivo therapies for genetic disorders.
July 06, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Precision BioSciences' renewed agreement with Prevail Therapeutics could potentially boost its product pipeline and future revenues.
The renewed agreement with Prevail Therapeutics, a subsidiary of a major pharmaceutical company, could potentially enhance Precision BioSciences' product pipeline and future revenues. This could positively impact the company's stock in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Eli Lilly's subsidiary, Prevail Therapeutics' collaboration with Precision BioSciences could potentially enhance its product offerings in the genetic disorders segment.
The collaboration with Precision BioSciences could potentially enhance Eli Lilly's product offerings in the genetic disorders segment. This could have a positive impact on Eli Lilly's stock in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 75